Related Experiment Video
Updated: Jun 29, 2026

05:20
A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl
Published on: November 28, 2014
13.1K
Cyclic Peptides Targeting Granzyme B: Potential Applications as PET Imaging Agents
1Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.
ACS Medicinal Chemistry Letters
|February 19, 2025
Summary
This patent reveals macrocyclic peptides that bind to Granzyme B (GzmB), enabling imaging of diseases linked to elevated GzmB. These peptides offer potential for diagnosing conditions like cancer immunotherapy, autoimmunity, and inflammation.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Molecular Imaging
Background:
- Granzyme B (GzmB) is a serine protease implicated in various physiological and pathological processes.
- Elevated GzmB levels are associated with conditions such as cancer immunotherapy, autoimmune diseases, wound healing, and inflammation.
- Novel diagnostic and imaging tools are needed to monitor GzmB activity in these disease states.

